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DAnalysis of the US Food and Drug Administration Manufacturer and
User Facility Device Experience database for adverse events involving
Amplatzer septal occluder devices and comparison with the Society of
Thoracic Surgery congenital cardiac surgery database
Daniel J. DiBardino, MD,a Doff B. McElhinney, MD,b Aditya K. Kaza, MD,a and John E. Mayer, Jr, MDa
Objective: Amplatzer (AGA Medical Corporation, Plymouth, Minn) septal and vascular occluder devices have
significantly altered the care of patients with congenital heart disease. The relative frequency and consequence of
complications resulting from the attempted placement of such devices, however, have not been well assessed. The
purpose of this study is to use large databases to assess the frequency and severity of such complications and com-
pare them with those of surgical atrial septal defect closure.
Methods: The US Food and Drug Administration Manufacturer and User Facility Device Experience database
was quarried for all adverse events for Amplatzer septal occluder devices, which were categorized and analyzed
with particular emphasis on management and outcome. The Society of Thoracic Surgery database was likewise
quarried for the same data regarding atrial septal defect closures over a contemporaneous time period. By using
a literature-derived denominator for total Amplatzer implant numbers, the results of the 2 therapies were com-
pared.
Results: Since July 1, 2002, 223 adverse events in patients undergoing Amplatzer atrial septal defect closure were
submitted to the Food and Drug Administration, resulting in 17 deaths (7.6%) and 152 surgical rescue operations
(68.2%). Society of Thoracic Surgery data demonstrated 1537 primary operations with 2 deaths (0.13%) and
6 reoperations (0.39%). By extrapolating on published estimates of Amplatzer implantation to provide an implant
denominator (n¼ 18,333), there was no difference between overall mortality for surgical (0.13%) and device clo-
sure (0.093%, P ¼ .649). Rescue operation for device adverse events (0.83%) was 2.1 times more likely than
reoperation for surgical closure (0.39%, P ¼ .063). Mortality per adverse event was higher for device closure
(7.6%) than for surgical closure (1.2%,P¼ .004), and the need for surgery per adverse event was higher for device
closure (68.2%) than for surgical closure (3.6%, P< .001). The mortality for surgical management of a device
adverse event (2.6%) was 20-fold higher than for primary elective atrial septal defect closure (0.13%, P<.0001).
Conclusion: Overall crude mortality for device and surgical closure atrial septal defect closure is equivalent, and
the need for subsequent operation (surgical rescue) is more common in patients undergoing device closure than
reoperation is in patients undergoing surgical closure. Complications from device closure tend to be serious and
most often require urgent or emergency operative management, whereas the mortality for surgical management of
a device complication appears higher than that of elective atrial septal defect closure. Further information is
required in the form of postmarketing surveillance, such as a mandatory user registry with periodic end-user
notification.
Congenital Heart Disease DiBardino et alEarn CME credits at
http://cme.ctsnetjournals.org
From the Departments of Cardiac Surgery a and Cardiology,b Children’s Hospital
Boston, Harvard Medical School, Boston, Mass.
Read at the Eighty-eighth Annual Meeting of the American Association for Thoracic
Surgeons, May 11–14, 2008, San Diego, California.
Received for publication May 25, 2008; revisions received Dec 26, 2008; accepted for
publication Feb 16, 2009.
Address for reprints: Daniel J. DiBardino, MD, Cardiac Surgery, Children’ s Hospital
Boston, 300 LongwoodAvenue, Boston, MA 02215 (E-mail: ddibardino@partners.
org).
J Thorac Cardiovasc Surg 2009;137:1334-41
0022-5223/$36.00
Copyright  2009 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2009.02.0321334 The Journal of Thoracic and Cardiovascular SuAmplatzer septal and vascular occluder devices (Amplatzer,
AGA Medical Corporation, Plymouth, Minn) have signifi-
cantly altered the care of patients with congenital heart
disease and are becoming standard care in many institutions.
The relative frequency, consequence, and cost of complica-
tions resulting from the attempted placement of the Amplatzer
occluder devices, however, have not been well assessed. The
overall mortality and need for surgical intervention are un-
known. In addition, periprocedural adverse events (AEs) for
catheter therapies often mandate operative intervention such
that an analysis of the patterns of such failures are germane
to the cardiac surgeon and essential to the cardiologist provid-
ing informed consent to patients and families. To generate
such data, an analysis was undertaken of the US Food and
Drug Administration (USFDA) on-line database for device-
related AEs, and a denominator of device implants wasrgery c June 2009
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DAbbreviations and Acronyms
AE ¼ adverse event
ASD ¼ atrial septal defect
MAUDE ¼ Manufacturer and User Facility
Device Experience
PER ¼ perforation/erosion/rupture
PFO ¼ patent foramen ovale
STS ¼ Society of Thoracic Surgery
USFDA ¼ US Food and Drug Administration
estimated from published literature. AEs involving surgical
atrial septal defect (ASD) and patent foramen ovale (PFO)
closure were likewise obtained from the Society of Thoracic
Surgery (STS) Congenital Cardiac Surgery Database, such
that a comparative analysis could be performed.
MATERIALS AND METHODS
The Manufacturer and User Facility Device Experience (MAUDE) data-
base was accessed via the USFDAmainWeb page.1 A query was performed
using the brand name ‘‘Amplatzer’’ to select for AEs involving all Amplat-
zer devices, and only the results for ASD and PFO closures were included in
this analysis. The first such reported AE was received by the USFDA on
January 24, 2002, and the search was arbitrarily concluded on June 30,
2007, for a total of a 5.5-year collection period. Events were broadly clas-
sified into categories (Table 1). If multiple AEs occurred within a single pa-
tient narrative, the event that dominated the clinical presentation and course
of the patient was used for classification purposes. Device ‘‘embolization’’
was defined by the movement of a device to a location other than the atrial
septum, differentiating it from device ‘‘malposition,’’ an unacceptable
position within the atrial septum. Cardiac perforation/erosion/rupture
(PER) was defined as any narrative where perforation, device erosion, or
rupture of a cardiac structure occurred or was thought to have occurred.
This is differentiated from the category of ‘‘pericardial effusion,’’ which
would be a serous effusion or one in which a perforation or erosion was
not suspected. Infection refers to cases in which the device was thought
to be the infectious source, and the thromboembolitic event category
included all stroke, transient ischemic attack, and device thrombus events.
All data regarding the manner in which complications were addressed
(catheter intervention, operative management, or both) and the final out-
come (mortality) were included in the analysis when sufficient information
was provided in the reported narrative. Any patient with death as the out-
come of the AE was listed as a device mortality, whereas all patients under-
going operation in the management of the AE were counted as ‘‘surgical
rescue.’’ To calculate the relative frequency of events, a request was
made to AGA Medical for estimates of implants over the study period.
This request was subsequently denied via electronic mail correspondence.
Thus, a previously published device estimate calculation was used to gener-
ate a denominator and allow comparison with STS data.
The STS Congenital Cardiac Surgery Database was likewise quarried for
the results of surgical closure of defects at the atrial septum during a similar
time frame (beginning January of 2002 with data available through Decem-
ber 2006). Patients with primary closure of PFO, primary ASD closure, and
patch closure of ASD as the primary qualifying index operation were
included in the analysis, whereas patients with other defects addressed at
the time of the index operation were excluded secondary to complexity
mismatch with device closure candidates. Outcomes were requested and
obtained for discharge mortality, postoperative length of stay, and a com-
plete list of any and all complications. From the complication tally, anyThe Journal of Thoracic and Cpatient undergoing an unplanned reoperation of any kind was counted in
the ‘‘surgical reoperation’’ group. The overall mortality rate of surgical
versus device closure was compared, as was the need for surgical rescue
compared with surgical reoperation. The rate of death per AE and need
for operation per AE were also compared for device versus surgical closure.
Because theMAUDE database narratives are widely and freely available
to the public on the World Wide Web and no patient identification variables
are included, there was no requirement for institutional review board
permission. Likewise, no such institutional permission is needed for the
use of STS data; permission was requested and granted from the STS data-
base committee. All data were coded using an Excel spreadsheet (Microsoft
Corp, Redmond,WA), and all percentages all reported with the accompany-
ing raw numeric data in the form of a fraction. Inferential statistics were
performed as 2-tailed chi-square analysis2 for categoric data.
RESULTS
Manufacturer and User Facility Device Experience
Database Adverse Events: Embolization and
Perforation/Erosion/Rupture
AE reports totaling 274 involving any type of Amplatzer
device were received over a 5.5-year period; closure of
TABLE 1. Major adverse event categories for patients reported to the
US Food and Drug Administration between January 1, 2002, and June
30, 2007
Adverse event
No. of reported
events
Percentage of
reported events
Device embolization 114 51%
Cardiac PERs 51 23%
Thromboembolitic
complication
11 5%
Residual/recurrent defect 9 4%
Device infection 5 2%
PER, Perforation/erosion/rupture.
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FIGURE 1. Histogram demonstrating the number of AEs involving the
Amplatzer (AGA Medical Corporation, Plymouth, MN) septal occluder
reported to the USFDA between January 2002 and December 2006. AE,
Adverse event.ardiovascular Surgery c Volume 137, Number 6 1335
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(Figure 1). Reliable morphologic data on the location within
the atrial septum was unavailable, and specific patient demo-
graphics and identifiers such as age, weight, body surface
area were likewise not found in the online reports. The spe-
cific Amplatzer system elements identified as the failing
component in the 232 AE narratives are listed in Table 2.
Careful review of each independent event narrative revealed
that multiple entries were sometimes found when multiple
devices were used for the same patient. Controlling for these
duplications resulted in 223 individual patients having AEs.
Death is listed as the outcome for 17 of 223 patients
(7.6% mortality per AE, Table 3). Cardiac PER was the
most frequent AE type resulting in mortality (10/17,
58.8%). One woman who survived perforation lost her
pregnancy, although this was not counted as mortality. To
provide a denominator for analysis, we relied on a published
precedent for implant estimate calculation used by Delaney
and colleagues,3 which was derived from published esti-
TABLE 3. Mortality among adverse events in 223 patients reported to
the US Food and Drug Administration between January 1, 2002, and
June 30, 2007
Number
Failing component
catalog number Adverse event type
1 9-ASD-022 Cardiac PER
2 9-ASD-000 Cardiac PER
3 9-ASD-020 Cardiac PER
4 9-ASD-026 Cardiac PER
5 9-ASD-026 Cardiac PER
6 9-ASD-019 Embolization
7 0-ASD-017 Thromboembolitic event
8 9-ASD-024 Embolization
9 9-ASD-022 Sudden death
10 9-PFO-HDE-025 Myocardial infarction
11 9-ASD-008 Respiratory failure
12 9-PFO-HAD-025 Cardiac PER
13 9-ASD-026 Cardiac PER
14 9-ASD-026 Cardiac PER
15 9-ASD-036 Cardiac PER
16 9-ASD-026 Cardiac PER
17 9-DEL-12F-45/80 Air embolization
PER, Perforation, erosion, rupture.
TABLE 2. Failing component listed for adverse events reported to the
US Food and Drug Administration between January 1, 2002, and June
30, 2007
Failing component
No. of reported
events
Percentage of
reported events
ASD occluder device 197 88.3%
PFO occluder device 16 7.2%
Delivery catheter 10 4.5%
Sizing balloon 6 2.7%
Guidewire 1 0.5%
Unknown 2 0.9%
ASD, Atrial septal defect; PFO, patent foramen ovale.1336 The Journal of Thoracic and Cardiovascular Sumates by a panel of physicians who were previously chosen
by AGAMedical to perform complication analysis and who
appear to be financially linked to the company.4 According
to these data, approximately 10,000 implants are estimated
over a 3-year period from 2002 to 2004. Extrapolation of
this rate over a 5.5-year period starting in 2002 gives
18,333 implants and an overall mortality of 17 of 18.333
(0.093%).
Embolization of Amplatzer occluder devices was the most
prevalent AE (114/223 patients, 51.1%), giving a national
embolization rate of 114 of 18,333 (0.62%). A 2004 survey
of AGA proctors determined the rate of embolization to be
21 of 3824 implants (0.55%), not significantly different
from our data (P¼ .599).5 There were 2 deaths, giving amor-
tality rate per embolization of 1.8%. Table 4 lists the sites
and relative frequencies of embolization, demonstrating
the most frequent embolization to the left side of the heart.
In 12 of the 114 cases (10.5%), a secondary arrhythmia oc-
curred with embolization and was often the ‘‘warning sign’’
of an AE, triggering further workup (Table 5). Eighty-eight
patients with embolization (77.2%) required operation,
whereas successful transcatheter management was possible
in 19 patients (16.7%). Management is not known for 5 pa-
tients (4.4%), and no action was taken in 2 patients (1.8%).
TABLE 4. Location of embolized devices among 114 patients reported
to the US Food andDrug Administration between January 1, 2002, and
June 30, 2007
Location
No. of reported
events
Percentage of
reported events
Right atrium 2 1.8%
Right ventricle 19 16.7%
Pulmonary artery 18 15.8%
Left atrium 28 24.6%
Left ventricle 12 10.5%
Aorta 21 18.4%
Unknown 14 12.3%
TABLE 5. Arrhythmia and device location among 114 patients with
device embolization reported to the US Food and Drug
Administration between January 1, 2002, and June 30, 2007
No. Rhythm disturbance (from narrative) Device location
1 Nonsustained VT Left ventricle
2 Atrial flutter Unknown
3 ‘‘Significant ectopy’’ Right ventricle
4 PVCs Right ventricle
5 PVCs Right ventricle
6 PVCs Right ventricle
7 Atrial fibrillation, complete heart block Pulmonary artery
8 ‘‘Transient arrhythmia’’ Left atrium
9 Bradycardia (with hypotension) Aorta
10 PVCs Right ventricle
11 ‘‘Extreme rhythm changes’’ Right ventricle
12 VT Right ventricle
VT, Ventricular tachycardia; PVC, premature ventricular contraction.rgery c June 2009
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(51/223, 22.9%). Mortality for this complication was 10 of
51 patients (19.6%), with 1 survivor losing her pregnancy
and at least 2 survivors described as having serious neuro-
logic morbidity. By similarly applying the previous esti-
mates, the national PER rate is 51 of 18,333 (0.28%). A
2004 publication by investigators affiliated with AGAMed-
ical determined the PER rate to be 9 in the known 9000 US
implants, giving a rate of 0.1%, which is significantly lower
than in our findings (P¼ .0003).4 Timing of the AE is listed
in Table 6; only 4 events occurred at implant, and whereas
most were clustered in the first 6 months, erosions and rup-
tures are still being reported as late as 3 years after deploy-
ment. Table 7 lists the confirmed or suspected locations of
cardiac PER; a location is specified in 40 patients and not
specified in 11 patients.
Some combination of atrium and aorta was found in 18
patients (35.3%, 18/51), whereas the atria alone were in-
volved in 13 patients (25.5%, 13/51). Both cases involving
the ascending aorta and 2 of the 3 left atrial appendage per-
forations were confirmed at surgery or autopsy. The other
left atrial appendage perforation was suspected by the im-
planting physician after frank hemopericardium occurred
within ‘‘a few hours’’ of the procedure. One patient died 4
hours after implant and was found to have a 1.5-mm right
upper pulmonary vein perforation at autopsy. A device ero-
sion through the atrial septum resulted in a new ASD that
was confirmed at catheterization and successfully treated
with a new device. Hemoptysis secondary to what the
implanting physician thought to be a pulmonary vein perfo-
ration developed in 1 patient; the procedure was immedi-
ately aborted, and this was successfully managed
nonoperatively. Likewise, an implanting physician sus-
pected perforation of the ‘‘left atrium or pulmonary vein’’
on review of a case of frank hemopericardium occurring
2.5 hours after the implant; the drainage slowed down, and
successful nonoperative management was used.
In the 11 cases of PER where the location is not specified,
3 cases were confirmed by successful surgical exploration,
but the location is unlisted in the narrative. An additional
TABLE 6. Timing of 51 cardiac perforations, erosions, or ruptures as
reported to the US Food and Drug Administration between January 1,
2002, and June 30, 2007
Timing of event
No. of reported
events
Percentage of
reported events
During implant 4 7.8%
Within 24 h 16 31.4%
Within 1 mo 11 21.6%
1–6 mo 8 15.7%
6 mo to 1 y 2 3.9%
>1 y 3 5.9%
Unknown 7 13.7%
PER, Perforation, erosion, or rupture.The Journal of Thoracic and C4 cases were described as sudden grossly bloody pericardial
effusions, but the location is unknown because each was
successfully treated nonoperatively by pericardial drainage.
The timing of 3 of these presentations was within 1 hour
(n ¼ 1) and within 24 hours (n ¼ 2) such that these were
most consistent with PER; in the fourth case, presenting at
1 month postimplant, erosion was suspected such that ‘‘sur-
gery was scheduled,’’ but no follow-up details of the opera-
tion are given. In 3 cases the location was unknown because
each was a death and limited autopsy data are given describ-
ing bloody fluid in the pericardium and left side of the chest,
making PER the most likely event. In the last unknown case,
an infant underwent cardiopulmonary resuscitation several
weeks after a device implant and was then found to have
a large effusion. It is unclear whether erosion occurred first,
mandating cardiopulmonary resuscitation, or erosion oc-
curred during the chest compressions and final outcome is
not given.
Surgical Outcome and Comparison Between
Databases
According to MAUDE narratives, 112 patients appear to
have been sent directly to the operating room (112/223,
50%), resulting in 2 operative deaths. Forty additional pa-
tients (40/223, 17.9%) were sent to the operating room after
failed catheter intervention to control the AE, resulting in 2
additional operative deaths. Summation gives 152 of 223
Amplatzer AEs (68.2%), ultimately requiring operative
management and an overall operative mortality for surgical
rescue of 2.6% (4/152).
STS data revealed that surgical closure of ASD and PFO
was performed in 1537 patients; primary closure was per-
formed in 457 patients (35 PFO and 422 ASD); and patch
TABLE 7. Confirmed or suspected locations of 51 cardiac perforation,
erosion, or rupture events, as indicated in the reports to the US Food
and Drug Administration between January 1, 2002, and June 30, 2007
Timing
No. of reported
events
Percentage of
reported events
Atrium and aorta 18 35.3%
Left atrium 8
Right atrium 5
Unlisted atrium 5
Atrium alone 13 25.5%
Left atrium 7
Right atrium 2
Unlisted atrium 3
Both atria 1
Unlisted 11 21.6%
Left atrial appendage 3 5.9%
Pulmonary vein 2 3.9%
Ascending aorta 2 3.9%
Atrial septum 1 2.0%
‘‘Left atrium or pulmonary vein’’ 1 2.0%ardiovascular Surgery c Volume 137, Number 6 1337
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tality was 2 patients (0.13%), and median length of stay was
3.0 days (quartiles 2 and 4 days). Any complication as defined
on the STS data harvest worksheets occurred in 167 of 1537
patients (10.9%). Serious complications, however, were rare;
no patient required a pacemaker (no permanent arrhythmia) or
any form of dialysis (temporary or permanent), 2 patients had
a persistent neurologic finding at discharge (0.13%), 3 pa-
tients had postoperative cardiac arrest (0.20%), and 6 patients
required unplanned reoperation (0.39%). There were no cases
of sternal dehiscence, mediastinitis, endocarditis, systemic or
pulmonary venous obstruction, phrenic, or recurrent laryngeal
nerve injury, and in no case was tracheostomy or mechanical
support required.
A comparison of the benchmark events (operative mortal-
ity, need for surgery and operative mortality, or need for sur-
gery per AE) for device and surgical closure was performed
(Table 8). Overall mortality for surgical (0.13%) and device
closure (0.093%) was similar (P ¼ .649). Rescue operation
for device closure (0.83%) was 2.1 times more likely than
reoperation for surgical closure (0.39%), closely approach-
ing statistical significance (P ¼ .063). Mortality per AE was
higher for device closure than surgical (7.6% vs 1.2%, P ¼
.004). Likewise, the need for surgery to control an AE was
higher for device closure (68.2% vs 3.6%, P< .001).
DISCUSSION
The MAUDE is a USFDA-driven reporting mechanism,
the purpose of which is to allow public access and review
of AEs involving medical devices.1 With the 1976 advent
of the Medical Device Amendments to the Federal Food,
Drug, and Cosmetic act, the FDA was charged with ensuring
the safety and efficacyof suchdevices.6,7Althoughpremarket
requirements are more stringent for class III (highest risk) de-
vices, there are several relevant examples in cardiovascular
medicine in which limitations of premarket analysis have
been exposed. Two examples from cardiac surgery include
theBjork-Shiley tilting disk prosthesis (Shiley Inc, Irvine, Ca-
lif) and the use of St Jude Silzone (St Jude Medical Inc, St
Paul,Minn) valve coating.7 For these andmany other reasons,
postmarketing surveillance has become an important focus
for the FDA. Voluntary reporting (focusing on the health
TABLE 8. Comparison of overall mortality, need for operation to
control adverse event mortality per adverse event, and need for
operation per adverse event between device closure and surgical
closure groups
Benchmark end point Surgery Device P value
Overall mortality 0.13% 0.093% .649
Need for operation 0.39% 0.83% .063
Mortality per AE 1.2% 7.6% .004
Operation per AE 3.6% 68.2% <.001
AE, Adverse event. ‘‘Need for operation’’ is defined as reoperation for surgical group
and need for surgical rescue for device group.1338 The Journal of Thoracic and Cardiovascular Scare professional) has been encouraged in 1973 and was for-
malized under the ‘‘MedWatch program in 1993. Important
steps were added in 1984, when Medical Device Reporting
regulations enforced mandatory manufacturer reporting, and
in 1990, when the Safe Medical Devices Act similarly
charged user facilities with the same reporting responsibility.
The MAUDE allows rapid access to these reports.
We acknowledge a priory the potentially serious limita-
tions of this analysis and have taken this into consideration
regarding the data we have chosen to report. Our experience
with MAUDE has confirmed that the events reported are es-
sentially all ‘‘sentinel events’’; they are the most serious,
life-threatening complications (of the device and related
hardware) that generated enough concern and exposure
that the physicians or user facilities thought that a report
was necessary. Procedural-related complications such as
access site problems (bleeding, infection, arteriovenous
fistula), blood transfusion, contrast allergy, anesthesia, and
airway problems and other commonly recognized catheter
complications are not captured by such a database. Further-
more, data from the General Accounting Office report that
less than 0.5% of all medical device AEs actually end up re-
ported to the FDA, a serious source of potential error in us-
ing these data as a national estimate.8 The STS database only
includes approximately half of the congenital centers in the
country and on a voluntary basis such that extrapolation of
results to all centers provides a source of potential error.
The STS database does not account for perception of pain
and other end points that would certainly confirm clear ad-
vantages to some aspects of catheter procedures. Perhaps
the most serious deficiency of the STS database, however,
is that the data are not longitudinal.
It is for these reasons that we choose to analyze death and
need for operation (surgical rescue vs surgical reoperation)
as benchmark end points; both are definitive categoric
(‘‘yes or no’’) outcomes of significant interest to clinicians
and patients. We believe that the issue of requiring an oper-
ation to control an AE is of particular interest given our find-
ing that the mortality rate of surgical rescue is 20-fold higher
than for elective repair. Thus, the argument that ‘‘the patient
is only getting the same operation they would have gotten
anyway’’ does not apply to operations for device complica-
tions. Attempts to group certain possible complications from
a procedure as ‘‘serious’’ or ‘‘potentially serious’’ are
fraught with numerous pitfalls and problems such that the
subject has itself become an independent science; it is well
beyond the scope of this article to breech this topic, and so
we make no such comparisons.
Results of the Manufacturer and User Facility Device
Experience Database and Society of Thoracic
Surgery
Comparing the embolization, PER, and thromboembolitic
event rates from the MAUDE database with the publishedurgery c June 2009
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same as was found in a 2004 survey of AGA proctors,5
whereas the PER rate is 3 times that reported in 2004 by
AGA investigators.4 Embolized devices often require oper-
ative intervention, and there is a risk of damage to cardiac
structures with catheter removal. Comparison of throm-
boembolitic event rates with other publications reveals that
it may be a bigger problem than is currently believed.
Only 1 such complication was found in 3 major studies
(including 2 specifically aimed at detecting thrombosis
rates),9-11 and a report in 2006 claims to be first to report
stroke from an Amplatzer device.12
Comparison with other publications also confirms a lower
published rate of death and serious complications than or find-
ings indicate.13-16 From 2003 to 2006, 5 case reports of device
erosion and perforation are found in the literature, and these
seem to be accounted for in theMAUDE database.17-21 Twice
before, investigators have published results of the reported
PER events from the MAUDE database,3,22 and there con-
tinues to be debate over the cause of this complication. The
findings of Divekar and colleagues22 highlight that larger de-
vices (>25 mm) do not seem to be overrepresented in the
known events and that many patients with oversized devices
do not experience perforation. We conclude that this seems to
be a more frequently encountered complication with a high
mortality but make no conclusions about cause.
CONCLUSIONS
The overall mortality for device and surgical closure of
the atrial septum seems equivalent, and the need for subse-
quent operation (surgical rescue) may be more common in
patients undergoing device closure than reoperation is in
patients undergoing surgical closure. Complications from
device closure tend to be serious and most often require
urgent or emergency operative management, whereas the
mortality for surgical management of a device complication
appears higher than that of elective ASD closure. Further
information is required in the form of postmarketing surveil-
lance, such as a mandatory user registry with periodic end-
user notification.
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Discussion
Dr Carl L. Backer (Chicago, Ill). I want to congratulate Dr Di-
Bardino and colleagues at Children’s Hospital Boston for their very
clever idea of mining the MAUDE database to determine the inci-
dence of adverse events involving the Amplatzer septal occluder
device. I first became aware of this database at the AATS in Tor-
onto in 2004 when Richard Jonas debated Andrew Reddington
about this very topic. A brief look at that MAUDE database is quite
an eye-opener.
This is a very timely presentation and an important analysis. The
issue of device closure was the first paper at the STS in the Plenary
Session this year. In that paper, Dr Tara Karamlou also mined a da-
tabase, the Nationwide Inpatient Sample and ICD-9 procedure and
diagnosis codes. She discovered an increased incidence of ASD
closure mostly due to a sudden and dramatic rise in percutaneous
closure beginning in the year 2001.
The comparison of the MAUDE database to the STS database
clearly demonstrates the importance of our own congenitalrdiovascular Surgery c Volume 137, Number 6 1339
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diologists complained that there is no MAUDE database for sur-
geons. The STS database is our answer to that issue.
I have three questions for you, and they relate to your numerator
and your denominator.
My first question relates to the numerator in your analysis. There
were 223 adverse events and 17 deaths related to the Amplatzer de-
vice. At the AATS meeting in 2006, when we had a similar discus-
sion, I asked this audience how many people had taken Amplatzer
devices out of various parts of the body; nearly everyone in the
room raised their hand. Is it possible that the MAUDE database
might only be capturing the tip of the iceberg, and how confident
are you in your numerator?
Dr DiBardino. Thank you Dr Backer. That’s a tricky question
to answer. I presented this data to the interventional cardiologists
in Boston before I left and it’s their sense that this is the tip of
the iceberg. There are folks who place these devices who don’t
know about the MAUDE database. And that makes me very suspi-
cious that our numerator is, in fact, grossly under-reported.
There was an interesting study published by the United States
General Accounting Office that stated that 0.5% of all device-re-
lated complications ever make it to the FDA—0.5%. And that
also makes me very wary of this numerator. I think that this is
the tip of the iceberg.
Dr Backer. My second question relates to the denominator. The
analysis of the predicted complication rate of the Amplatzer device
hinges on this number. You noted in your manuscript that a request
of AGA Medical was made for an estimate of implants over the
time of the study period and that this request was denied. You de-
rived an estimate of 18,333 implants, although the paper you
quoted was from 2004. This makes the calculated mortality of
the Amplatzer device 1 in 1,000. How comfortable are you with
the denominator that you have given us?
Dr DiBardino. Well, the 2 papers that I mentioned (from 2004
and 2007) were both papers that used implants estimates based on
AGA medical data and the 2004 paper was published by folks fi-
nancially tied to AGA medical. So the number 18,333 comes
from an estimation that was made of implants over about a 2-
and-a-half year period; we simply converted that estimate into
‘‘number of implants per month’’ and multiplied it by 66 months,
or 5.5 years. I think it’s the best we can do. I can’t speak to its ac-
curacy because I cannot externally validate it, but I do submit that it
is an honest effort and the best we can do.
Dr Backer.Andwhat about the company not responding to your
requests?
Dr DiBardino.Well, yes, it was actually interesting. I called the
Boston AGAMedical representative (who services Children’s Hos-
pital Boston) and asked for the actual implant numbers. They
looked into it, and I received an electronic mail correspondence
subsequently that said that that information would not be available
for me. I just can’t get it.
Dr Backer. All right. My final question relates to the incidence
of complications in the MAUDE database over time. It was a little
disturbing to see that slide that showed that actually the number of
reports are increasing per year. This could possibly be related to an
increase in the total number of devices implanted or that there is not
a positive learning curve that we would hope would happen. When
we discussed this in 2006, Dr del Nido noted that the interventional1340 The Journal of Thoracic and Cardiovascular Sucardiologists are now looking at things like the size of the aortic
rim, not oversizing the device, more careful follow-up, and that
this would, indeed, actually reduce the incidence of these compli-
cations. What’s your feeling, looking at this database, whether
the incidence of these complications is going up or down over time?
Dr DiBardino. Well, the histogram that I showed is not very
useful because it, of course, does not answer the question about
whether the increase in reported events is simply that people are re-
porting them more often or are they being implanted more often
such that the frequency of complications cannot be ascertained.
The cardiology literature does comment on the fact that, after the
device was first approved for general use, there was perceived to
be a rise in the complication rate and this has been ascribed to
the unfamiliarity of new cardiologists to that device. Beyond
around 2004–2005, we sort of lose track of that in the literature. I
really don’t have enough information to truly accurately know
what the trend is in complication rate.
Dr Jeffrey P. Jacobs (St. Petersburg, Fla). First, I would like to
congratulate you for doing a great job and making an outstanding
presentation. It really makes me proud to see our database, the
STS Congenital Heart Surgery Database, mature to the point that
it can be used for a study like this one. I think you did a great job
with this study and presented it quite well.
I think one could criticize the data from the STS database by say-
ing that it stops at hospital discharge, and we do not knowwhat hap-
pens after hospital discharge. This criticism underscores the
importance of what we are trying to accomplish in the STS database
by incorporating HIPAA Compliant Unique Patient, Surgeon, and
Hospital Identifier Fields into the STS Database, and creating
a framework where our database can be used as a tool for longitu-
dinal follow-up. The STS Adult Cardiac Database has incorporated
these identifier fields as of January 1, 2008. These fields will be in-
corporated into the STS Thoracic Database on January 1, 2009, and
into the STS Congenital Heart Surgery Database on January 1,
2010. I think that this accomplishment is going to mature our
STS database.
My question is: How would you recommend maturing the way
that we follow these devices, and the device databases, based on
what you have learned from this study?
Dr DiBardino. Thank you, Dr Jacobs. In my time as a junior
resident in general surgery in Dr Chuck Fraser’s research lab, I be-
came interested in databases and outcomes analysis and hope to
make that the backbone of my own academic career as I progress.
I think the answer to your question is that if you look at the his-
tory of the FDA in cardiovascular surgery, there are numerous ex-
amples (the Bjork-Shiley prosthesis, the Silzone coating that was
transiently used on St. Jude valves) of where postmarketing surveil-
lance has become important. Even changed the way products are
handled, what their recommendations are for their placement and,
in some cases, products being eliminated from the market. I think
what we’re not going to have is a head-to-head trial. It’s just not go-
ing to happen. I think an easy solution would be simply creating
a registry, an implant registry, with periodic end-user notification.
That has been done with LVADs; it is easy and effective and it
would give us real answers about what the numerators and denom-
inators are.
Dr Shunji Sano (Okayama City, Japan). Just over one year, we
studied theAmplatzerASDclosure. In the last year, our cardiologistsrgery c June 2009
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sure on 10 patients. And we have no host mortality and no surgical
rescue, one temporary episode of thromboembolism. So the result
is completely different from yours. I think maybe the difference is
the indication. If you have wide range of indications, you have
more complications.
The question is: Do you have surgeons involved in the indication
of Amplatzer ASD closure and surgical closure? Because we, in our
unit, the surgeon is completely involved in the indication of the
technique, 2 techniques, and our young surgical fellow is also in-
volved in this procedure.
Dr DiBardino. Well, I think what you’re describing is very
common when you examine the results from a single center that
has excellent physicians who are doing procedures that they are
very experienced with. And if you look at single-center reporting
from the United States, you’ll find the results that you’ve just de-
scribed: No mortality, no erosions, no embolizations. But whenThe Journal of Thoracic and Cyou apply a product to the general audience and you allow people
who are less familiar with it, then, to start using it, there is going to
be a learning curve. And I think that’s part of what we’re seeing in
this analysis.
In Boston, the surgeons are not involved in the decision, by and
large, to place implants or devices. One thing I will say, however, is
that our interventionalists (one of whom is my coauthor on this
paper) are gifted and talented but also careful. What I mean to say
is that they are very careful about their selection and techniques in
terms of using stop-flow technique for balloon sizing, paying careful
attention to the amount of retro-aortic rim, and being very careful not
to oversize devices. They’re probably more careful about it than
they are at some other places and there not afraid to send certain
patients to the operating room. All of this leads, as it has at your cen-
ter, to a low complication rate. But I think that it’s difficult to extrap-
olate those results to everywhere, all over, because of the different
comfort level and skill level of the physicians who provide care.ardiovascular Surgery c Volume 137, Number 6 1341
